By Fineline Cube Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its incubated company Signet Therapeutics to establish an AI-driven precision prevention and treatment system for gastric cancer. The collaboration will create a joint venture in China and Singapore to build a comprehensive “early screening, diagnosis, and treatment” closed-loop system within five years.
Partnership Structure & Strategic Terms
| Item | Detail |
|---|---|
| Companies | Mirxes Singapore / XtalPi Inc. (QuantumPharm) / Signet Therapeutics |
| Joint Venture | To be established in China and Singapore |
| Focus | Gastric cancer precision prevention and treatment |
| Coverage | Early screening, diagnosis, and treatment |
| Technology Stack | Mirxes early screening + XtalPi AI drug R&D + Signet targeted drugs |
| Timeline | 5‑year roadmap to build closed‑loop system |
| Market Target | Asian market expansion |
Technology Integration & Competitive Advantage
- Mirxes Contribution: Globally leading gastric cancer early screening technology
- XtalPi Platform: AI and robotics‑powered drug R&D platform for accelerated discovery
- Signet Pipeline: World‑first targeted drug pipeline for diffuse gastric cancer
- Synergistic Value: Combined platform creates end‑to‑end solution from detection to treatment, addressing unmet need in high‑prevalence Asian markets
Market Impact & Commercial Outlook
- Gastric Cancer Burden: Asia accounts for 70% of global gastric cancer cases; China alone sees 480,000 new cases annually
- AI‑Driven Market: Precision oncology market projected to reach $15 billion : by 2030; AI‑enabled screening and companion diagnostics growing at 25% CAGR
- Revenue Potential: Analysts estimate the joint venture could generate $500–800 million : in annual revenue by 2030 across screening, diagnostics, and therapeutics
- Strategic Validation: Multi‑party collaboration validates Mirxes’ screening platform and XtalPi’s AI capabilities while de‑risking Signet’s novel pipeline
- Next Steps: Joint venture formation expected Q2 2026; first integrated screening‑treatment pilot programs to launch in Tier‑1 Chinese hospitals by Q4 2026
Forward‑Looking Statements
This brief contains forward‑looking statements regarding joint venture formation timelines, market penetration, and revenue projections for the gastric cancer precision system. Actual results may differ due to regulatory approvals, clinical trial outcomes, and competitive dynamics.-Fineline Info & Tech